Showing results (1741-1750 of 8,886) with videos related to
Sort By:
Pageof 889
European Urology|July 6, 2023
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Matthias Eiber, Tobias Maurer, et al.European Urology|June 18, 2023
What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines PanelFawzy Farag, Vasileios I Sakalis, Serenella Monagas Arteaga, et al.European Urology|December 4, 2018
Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTubeStacy Loeb, Shomik Sengupta, Mohit Butaney, et al.European Urology|September 25, 2020
Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per CapitaJeremy Yuen-Chun Teoh, Junjie Huang, Wendy Yuet-Kiu Ko, et al.European Urology|January 1, 1988
Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumorsF Calais da Silva, L Denis, A Bono, et al.European Urology|January 1, 1988
Paratesticular rhabdomyosarcoma in adolescentsK K Ketiku, J O Esho, M V AzodoEuropean Urology|January 1, 1988
Treatment of hydrocele testis by injection of tetracyclineJ Miskowiak, A B ChristensenEuropean Urology|December 26, 2019
Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active SurveillanceGregory T Chesnut, Emily A Vertosick, Nicole Benfante, et al.European Urology|August 31, 2020
Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-GuérinRoger Li, Scott M Gilbert, Ashish M KamatEuropean Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.Pageof 889